BridgeMD
New treatment option for Bronchiolitis Acute Viral
Official title Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age
ClinicalTrials.gov ID: NCT05444699
What this study is testing
What is Prednisolone Sodium Phosphate?
Prednisolone Sodium Phosphate is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for bronchiolitis acute viral.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of the trial is to evaluate whether the use of oral prednisolone directed by point-of-care testing is useful in acute wheezing caused by rhinovirus in children aged 6-24 months.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 24
You may be able to join if
- Wheezing bronchitis diagnosed by a physician
- Need for salbutamol treatment at the emergency department
- Positive nasopharyngeal rhinovirus or picornavirus finding in point-of-care testing
You likely can't join if
- Need for immediate resuscitation
- Immediate transfer to ICU
- Suspected pneumonia based on the auscultation finding
- Suspected serious bacterial infection
- Other respiratory virus finding in the absence of rhinovirus or picornavirus
- Positive respiratory syncytial virus finding
See the full eligibility criteria
- Wheezing bronchitis diagnosed by a physician
- Need for salbutamol treatment at the emergency department
- Positive nasopharyngeal rhinovirus or picornavirus finding in point-of-care testing
- Need for immediate resuscitation
- Immediate transfer to ICU
- Suspected pneumonia based on the auscultation finding
- Suspected serious bacterial infection
- Other respiratory virus finding in the absence of rhinovirus or picornavirus
- Positive respiratory syncytial virus finding
- Positive SARS-coronavirus-2 finding
- Positive Mycoplasma pneumoniae finding
- Positive Bordetella pertussis finding
- Contact with a person with chickenpox within 14 days
- Active chickenpox
- Suspected foreign body of the respiratory tract
- Immunosuppressive treatment
- Systemic corticosteroid treatment within 14 days
- Allergy to corticosteroids
The study team makes the final eligibility decision.
Where it's taking place
- Kokkola, Finland
- Oulu, Finland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 months to 24 months. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kokkola, Finland; Oulu, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.